A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Study sponsor: Angiodynamics, Inc. · ANGO
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-04Estimated
Enrollment · participants528Estimated
Source updated2025-02-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.